Amgen Executives Trade Quietly: CTO David Reese Sells 6,022 Shares Amid Routine Insider Activity, No Sign of Strategic Exit.

Amgen Insider Trading Snapshot – March 16, 2026 The latest Form 4 filings from Amgen’s senior management show a quiet day of activity. Chief Technology Officer David Reese sold 6,022 shares of common stock—about 0.8 % of his holdings—at the market price of $366.21. The sale, triggered by the vesting of 744 dividend equivalents, is a routine exercise of the company’s equity incentive plan and does not alter the overall ownership picture.

What the Sale Means for Investors Reese’s transaction is modest in scale and is part of a broader pattern of share purchases and sales by Amgen executives over the past year. The sale does not signal a lack of confidence; on the contrary, the same day saw the EVP of Operations, Santos Esteban, and the CFO, Griffith Peter, selling shares, while other executives such as Bradway Robert and Miller Derek added shares. The mix of buys and sells reflects normal portfolio rebalancing rather than a coordinated exit.

From a pricing perspective, the stock’s price movement was flat on the day of the filing (price unchanged at $351.48), and the company’s weekly, monthly, and yearly performance trends remain largely unchanged. The 52‑week high of $391.29 and a year‑over‑year increase of 11.2 % suggest that the market still values Amgen’s long‑term pipeline, despite the quarterly dip.

Reese’s Insider Profile David Reese has been a steady investor in Amgen. In March 2026, he added 12,063 shares (buy) and, in May 2025, he bought 22,944 shares of restricted stock units (RSU) and 3,549 shares of common stock. His holdings now stand at 41,787 shares, a 19 % increase from the previous reporting period. Reese’s activity is typical for a technology lead in a biotech firm: buying during periods of strong pipeline development and exercising RSUs when they vest. Historically, his trades have been priced near the market, indicating no attempt to time the market and a focus on long‑term value.

Broader Insider Activity Context On March 16, 2026, other insiders also transacted: the EVP of Operations sold 5,621 shares, the CFO sold 5,748 shares, and the EVP‑Gen Counsel sold 5,353 shares each. These transactions were all executed at the same price, reinforcing the view that the moves are part of a standard equity program rather than reaction to specific corporate events. No insider has reported a change in control or a significant shift in their stake, keeping the company’s ownership structure stable.

Investor Takeaway The current insider activity is routine and should not be interpreted as a red flag. Amgen’s leadership continues to participate in the equity plan, signaling confidence in the company’s trajectory. Investors should view these trades as standard portfolio management, while remaining alert to future earnings reports and product pipeline developments that could influence share price more directly.